AbCellera announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. Dr. Lo is a cofounder and director of BridgeBio Pharma, a director of Atomwise and Roivant Sciences, a cofounder and chairman of QLS Advisors, and a member of the advisory boards of NCATS and the American Cancer Society’s BrightEdge Impact Fund. He is currently the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT'sComputer Science and Artificial Intelligence Laboratory. Dr. Hamer, Managing Partner at DCVC Bio, joined AbCellera’s Board in 2018 and has served on the Audit and Compensation Committees.